CXCR4 is the most common chemokine receptor expressed on the surface of many cancer cell types. In comparison to normal cells, cancer cells overexpress CXCR4, which correlates with cancer cell metastasis, angiogenesis, and tumor growth. CXCR4 antagonists can potentially diminish the viability of cancer cells by interfering with CXCL12-mediated pro-survival signaling and by inhibiting chemotaxis. Herein, we describe a series of CXCR4 antagonists that are derived from ()-5,6,7,8-tetrahydroquinolin-8-amine that has prevailed in the literature. This series removes the rigidity and chirality of the tetrahydroquinoline providing 2-(aminomethyl)pyridine analogs, which are more readily accessible and exhibit improved liver microsomal stability. The medicinal chemistry strategy and biological properties are described.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767887PMC
http://dx.doi.org/10.1021/acsmedchemlett.7b00381DOI Listing

Publication Analysis

Top Keywords

cxcr4 antagonists
12
cancer cell
8
cancer cells
8
cxcr4
5
synthesis sar
4
sar 1234-tetrahydroisoquinoline-based
4
1234-tetrahydroisoquinoline-based cxcr4
4
antagonists cxcr4
4
cxcr4 common
4
common chemokine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!